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Abstract
Premature ovarian failure (POF) is a primary ovarian defect characterized by absent menarche
(primary amenorrhea) or premature depletion of ovarian follicles before the age of 40 years
(secondary amenorrhea). It is a heterogeneous disorder affecting approximately 1% of women <40
years, 1:10,000 women by age 20 and 1:1,000 women by age 30. The most severe forms present
with absent pubertal development and primary amenorrhea (50% of these cases due to ovarian
dysgenesis), whereas forms with post-pubertal onset are characterized by disappearance of
menstrual cycles (secondary amenorrhea) associated with premature follicular depletion. As in the
case of physiological menopause, POF presents by typical manifestations of climacterium: infertility
associated with palpitations, heat intolerance, flushes, anxiety, depression, fatigue. POF is
biochemically characterized by low levels of gonadal hormones (estrogens and inhibins) and high
levels of gonadotropins (LH and FSH) (hypergonadotropic amenorrhea). Beyond infertility,
hormone defects may cause severe neurological, metabolic or cardiovascular consequences and
lead to the early onset of osteoporosis. Heterogeneity of POF is also reflected by the variety of
possible causes, including autoimmunity, toxics, drugs, as well as genetic defects. POF has a strong
genetic component. X chromosome abnormalities (e.g. Turner syndrome) represent the major
cause of primary amenorrhea associated with ovarian dysgenesis. Despite the description of several
candidate genes, the cause of POF remains undetermined in the vast majority of the cases.
Management includes substitution of the hormone defect by estrogen/progestin preparations. The
only solution presently available for the fertility defect in women with absent follicular reserve is
ovum donation.
Disease name and synonyms
Premature ovarian failure (POF; POF1: OMIM 311360);
Hypergonadotropic ovarian failure; Menopausa precoce.
Included diseases
POF2 (OMIM #300511); POF3 (OMIM #608996)
Definition
Premature ovarian failure is defined as a primary ovarian
defect characterized by absent menarche (primary amen-
orrhea) or premature depletion of ovarian follicles/
arrested folliculogenisis before the age of 40 years (sec-
ondary amenorrhea) [1,2].
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Epidemiology
POF affects approximately: one in 10,000 women by age
20; one in 1,000 women by age 30; one in 100 women by
age 40 [3]. The familial form of POF is rare, representing
4 to 31% of all cases of POF [4-6].
Etiology
The causes of POF are extremely heterogeneous. Acquired
forms such as those occurring after treatments for neo-
plastic diseases or autoimmune diseases account for many
cases [1]. POF has a strong genetic component with X
chromosome abnormalities playing a primary role mainly
in the cases with ovarian dysgenesis [7-10]. A gene (or
genes) for POF (POF1) was localised to Xq21.3–Xq27 on
the basis of deletions in various patients and families. A
second gene (or genes) for POF (POF2) implicated by the
analysis of balanced X/autosomal translocations has been
localised to Xq13.3–q21.1. Despite the description of sev-
eral candidate genes [11-16], the cause of POF still
remains undetermined in the majority of the cases (idio-
pathic). This idiopathic form of POF can show sporadic
and familial forms.
The different causes of POF are illustrated as follows:
• Iatrogenic origin (surgery, chemotherapy, radiations);
• Autoimmune, including polyglandular autoimmune
syndrome, as well as autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy (APECED) due to
mutations in AIRE gene);
• Infections (e.g. herpes zoster, cytomegalovirus);
• Chromosome X defects:
■  Turner syndrome
■  Fragile X syndrome (FMR1 gene premutation)
• Monogenic defects
■  Syndromic defects:
❍  Congenital disorders of glycosylation (CDG, formerly
named carbohydrate-deficient glycoprotein syndromes)
(recessive)
❍  Galactosemia (recessive)
❍  Blepharophimosis-ptosis-epicanthus inversus syn-
drome (BPES) (female-limited, dominant)
❍  Pseudohypoparathyroidism (PHP) type Ia (parental
imprinting : maternal inheritance)
■  Isolated defects:
❍  Follicle stimulating hormone (FSH) receptor mutations
(FSHR), (recessive)
❍  Luteinizing hormone (LH) receptor mutations (LHR),
(recessive)
❍  FOXL2 (transcription factor involved in BPES) muta-
tions (female-limited defect, dominant)
❍  Bone morphogenetic protein 15 (BMP15) mutations
(female-limited defect, heterozygous mutation)
• Idiopathic
Defects in some of these candidate genes may present
with different phenotypes. FOXL2  defects may present
either with BPES type 1 (without POF) or with BPES type
2 (with POF), condition designated as POF3 [14]. Rarely,
FOXL2  mutations may be associated with POF in the
absence of eyelid/palpebral alterations (isolated POF)
[17,18]. Depending on the degree of FSH resistance, FSHR
defects are associated with primary [12] or secondary
amenorrhea [13,19]. Mutations in LHR  have been
described in women with secondary amenorrhea (charac-
terized by elevated serum LH/FSH ratio and cystic follicles
at ultrasound) belonging to pedigrees of male patients
with Leydig hypoplasia [20]. Two of the candidate genes
are located on the X chromosome. FMR1 gene (Xq27.3)
mutations or pre-mutations are typically associated with
secondary amenorrhea in female relatives of male patients
with mental retardation [8]. BMP15 gene (Xp11.2) defect
has so far been described in two sisters with primary
amenorrhea and heterozygous for the mutation. This
defect represents an unusual example of a X-linked disease
in which affected females inherit the mutation from their
unaffected father [15].
Clinical description
The symptoms can vary considerably from patient to
patient and the disorder may occur abruptly or spontane-
ously or it may develop gradually over several years. The
most severe forms of hypergonadotropic ovarian failure
present with absent pubertal development and primary
amenorrhea [2,21]. The clinical picture is characterized by
absent menarche and pubertal delay results in absent sex-
ual maturation and reduced growth velocity. In the
female, pubertal delay is defined as the absence of mam-
mary and pubic hair development and menarche at 13
years. Moderate hirsutism may be seen due to the action
of androgens originating from adrenals.
About half of the cases of primary amenorrhea are due to
ovarian dysgenesis, which is revealed by the finding ofOrphanet Journal of Rare Diseases 2006, 1:9 http://www.OJRD.com/content/1/1/9
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streak ovaries accompanied by uterus hypoplasia at ultra-
sound. In the other patients, follicles (<10 mm) may be
found at histological evaluation such as in the case of
FSHR  mutations [22]. In these cases, almost normal
pubertal development may be seen.
Post-pubertal onset of ovarian failure represents the large
majority of the cases [1]. This is characterized by second-
ary amenorrhea associated with premature follicular
depletion or arrested folliculogenisis. As in the case of
physiological menopause, POF is clinically characterized
by typical manifestations of climacterium such as palpita-
tions, heat intolerance, flushes, night sweats, irritability,
anxiety, depression, sleep disturbance, decreased libido,
hair coarseness, vaginal dryness, fatigue.
Female infertility is an obvious and presently irreversible
consequence of POF. Importantly, POF and prolonged
lack of estrogen treatment may lead to the early onset of
osteopenia and osteoporosis. Moreover, sexual hormone
defects represent an important risk factor for frequent and
severe neurological, metabolic or cardiovascular disorders
such as Alzheimer's disease, hypercholesterolemia or
ischemic diseases.
Hypergonadotropic ovarian failure may be part of other
syndromic features (see the causes of POF): Autoimmune
polyendocrinopathy-candidiasis-ectodermal dystrophy,
Blepharophimosis-ptosis-epicanthus inversus syndrome,
Carbohydrate-deficient glycoprotein syndromes, Galac-
tosemia, Turner) and PHP I.
PHP I is associated with mutation in the GNAS  gene
encoding Gs protein alpha [23]. The diagnosis of PHP I is
based on the findings of resistance to several peptide hor-
mones acting through the adenylyl cyclase/cAMP path-
way. The key findings are elevated parathyroid hormone
(PTH) with low/normal calcemia, high thyrotropin (TSH)
with normal thyroid hormone levels, growth hormone
deficiency and high gonadotropins in patient with
delayed puberty and skeletal abnormalities (Albright
osteodystrophy). PHP I syndrome occurs when the
mutant allele is inherited from the mother, due to the
imprinting of the paternal GNAS allele in the affected tis-
sues.
The early diagnosis of familial POF will provide the
opportunity to predict the likelihood of early menopause,
and allow other reproductive choices to be made, such as
freezing embryos or having children earlier. As POF has
cumulative negative effects over time, it is important for
clinicians to make a timely diagnosis and begin appropri-
ate strategies for symptom management, emotional sup-
port, and risk reduction.
Diagnostic methods
Both primary and secondary forms of ovarian failure are
biochemically characterized by low levels of gonadal hor-
mones (estrogens and inhibins) and high gonadotropins
(LH and FSH) (hypergonadotropic amenorrhea). The ele-
vation of FSH is usually more marked than that of LH and
an FSH value >30 U/L is indicative of ovarian failure.
Ultrasound frequently reveals small ovaries without evi-
dence of growing follicles. In the cases with primary
amenorrhea, gonadal dysgenesis is documented by the
finding of streak ovaries. Histological examination of
biopsies performed during pelvic laparoscopy in the case
of hypoplastic ovaries (0.20–0.30 ml on ultrasound) may
reveal the presence of primary follicles. Forms of POF
linked to the finding of ovarian cysts may be due to LH
resistance (LHR mutations) which presents with second-
ary amenorrhea. In contrast to what is generally found in
POF, defects in LH receptor are typically associated with a
serum LH elevation (> 10 U/L) more pronounced than
that of serum FSH. The evaluation of other peptide factors
of ovarian origin, such as inhibin B and anti-mullerian
hormone (AMH), may be useful to determine the follicu-
lar reserve when POF is suspected. Low levels of inhibin B
may predict follicular depletion before the large FSH rise.
Karyotype evaluation and other cytogenetic investigations
are useful to identify major X chromosome abnormalities.
Differential diagnosis
The differential diagnosis is based on the exclusion of
other causes of primary and secondary amenorrhea
(absence of menstruation for more than 6 months).
Parameters useful for the exclusion of each of the follow-
ing conditions are illustrated:
• Pregnancy: high chorionic gonadotropin (CG) levels.
• Iatrogenic causes (surgery, anti-neoplastic treatments,
radiations, antidopaminergic drugs): complete anamnes-
tic investigation.
• Hypothalamic-pituitary disease (pituitary tumors,
hyperprolactinemia, Kallmann syndrome, ....): high prol-
actin (PRL) and low/normal gonadotropin levels, altera-
tions at imaging of brain/sella region.
• Hypothalamic amenorrhea (induced by stress, intensive
exercise, anorexia, weight loss, fasting, severe diseases,):
low/normal gonadotropin levels.
• Polycystic ovaries: alterations at ovarian ultrasound,
normal gonadotropin and high androgen levels.Orphanet Journal of Rare Diseases 2006, 1:9 http://www.OJRD.com/content/1/1/9
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• Enzymatic defects of steroidogenesis (e.g. 21-hydroxy-
lase deficiency): alterations at physical and adrenal ultra-
sound, normal gonadotropin, high androgen and
adrenocorticotropic hormone (ACTH) levels.
• Endocrine disorders, such as hyperthyroidism, hypothy-
roidism, Cushing syndrome: complete clinical/biochemi-
cal evaluations, normal gonadotropin levels.
• Only in patients with primary amenorrhea:
- vaginal/uterus anatomical abnormalities, such as Roki-
tanski syndrome or Asherman syndrome: alterations at
physical examination/pelvic ultrasound, normal gonado-
tropin levels.
- disorders of sexual differentiation (e.g.  resistance to
androgens): alterations at physical/ultrasound examina-
tion, evaluation of karyotype, measure androgen/anti-
mullerian hormone levels.
Genetic counseling
Genetic counseling is nowadays recommended for several
reasons, when a genetic form of POF is suspected or iden-
tified.
Counseling is of particular importance in POF cases from
families with X-linked mental retardation (Fragile X syn-
drome). Fragile X syndrome is due to CGG expansion
(>55 repeats) at the 5'UTR of FMR1 gene (Xq27.3). The
expansion of CGG repeats is associated with gene silenc-
ing resulting in male mental retardation and in POF with
secondary amenorrhea in female carriers [8].
Genetic investigations may be useful for the early diagno-
sis of genetic defects underlying POF, when a female is
born from a family with other female members affected
with POF. Pedigree studies on affected families showed a
mode of inheritance suggestive of autosomal dominant
sex-limited transmission or X-linked inheritance with
incomplete penetrance. In families with POF, the risk of
other females developing POF will depend on the mode
of inheritance and the mode of transmission. With auto-
somal dominant inheritance, the risk of POF will be 50%
with either maternal or paternal transmission. However,
with X-linked inheritance and paternal transmission this
risk may be as high as 100%. These risks will be smaller
with incomplete penetrance. If a POF patient appears to
be a sporadic case, the risk of other female relatives devel-
oping POF will probably be equal to the risk in the general
population.
All women who experience POF before the age of 30 years
should perform a blood test for chromosomal assessment.
Older women should discuss the option of chromosomal
studies, as identification of abnormality may influence
other family members, sisters or daughters, who carry the
same defect in term of planning pregnancies. Carriers of
the genetic defect may be advised for early pregnancy or
oocyte collection and preservation.
Antenatal diagnosis
Not relevant at present.
Management
Patients with POF have infertility and hormone deficits.
At present, fertility cannot be restored if the diagnosis is
made after complete follicular depletion. In some cases,
early diagnosis by genetic investigation may instead lead
to advice for early conception or oocyte harvesting and
preservation. Hormone defect may be substituted by
estrogen/progestin preparations. The only solution pres-
ently available for the fertility defect in women with
absent follicular reserve is represented by ovum donation.
Unresolved questions
In most of the isolated defects the cause is still unknown.
Several candidate genes have been identified, but causa-
tive mutations have been found in a strict minority of
patients [7,11,15,16]. The prevalence of some genetic
defects remains to be determined (e.g. BMP15 mutations).
Though one paper described auto-antibodies against
FSHR in a series of women with POF [24], auto-antigens
and specific auto-antibodies for the diagnosis of autoim-
mune forms of isolated POF remain to be determined.
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